Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T + N-803 in mAPMR Prostate Cancer
NCT07756593Phase 1Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of nogapendekin alfa inbakicept in prostate cancer (PCa) (5 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Frequency of dose-limiting toxicities at 44 days, Recommended Phase II Dose at 44 days and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07756593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756593.